XML 34 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2
Collaboration and Other Agreements, Takeda (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
May 31, 2014
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Collaboration And Other Agreements [Line Items]            
Deferred revenue included in current liabilities   $ 3,783   $ 3,783   $ 5,866
Deferred revenue included in long-term liabilities   9,794   $ 9,794   12,631
Takeda Pharmaceutical Company Limited [Member]            
Collaboration And Other Agreements [Line Items]            
Non-refundable upfront payment $ 15,000          
Takeda Pharmaceutical Company Limited [Member] | Research Collaboration And License Option Agreement [Member]            
Collaboration And Other Agreements [Line Items]            
Collaboration or other agreement date       September 2014    
Amount allocated to agreement 5,000          
Recognized revenue under agreement     $ 500   $ 1,100  
Takeda Pharmaceutical Company Limited [Member] | Takeda MGD010 Agreement [Member]            
Collaboration And Other Agreements [Line Items]            
Collaboration or other agreement date       May 2014    
License option fee   15,000   $ 15,000    
Amount allocated to agreement $ 10,000          
Expected period of development       24 months    
Recognized revenue under agreement   800 $ 1,300 $ 2,100 6,800  
Milestone received         $ 3,000  
Deferred revenue   0   0   2,100
Deferred revenue included in current liabilities   0   0   $ 2,100
Takeda Pharmaceutical Company Limited [Member] | Takeda MGD010 Agreement [Member] | Maximum [Member]            
Collaboration And Other Agreements [Line Items]            
Potential clinical and regulatory milestone payments   93,000   93,000    
Potential sales milestone payments under agreement   $ 375,500   $ 375,500